Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00078546 · ClinicalTrials.gov registry record · Phase 1
EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)
A Phase 1 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00078546 is a Phase 1 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 12 participants.
The verdict
NCT00078546, a Phase 1 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
To determine the safety of the combination of CD45 monoclonal antibody (Mab) followed by intravenous injection of EBV specific CTL in patients with nasopharyngeal cancer. To compare the expansion, persistence and anti-tumor effects of the EBV specific CTL given after CD45 Mab administration with that observed in our first study. To obtain preliminary information on the safety and response to an extended dosage regimen of EBV-specific CTL in patients, who have stable disease or a partial response after the initial dose of EBV-specific CTL.
Interventions
- BIOLOGICAL EBV specific CTL Infusion
- BIOLOGICAL Anti CD45 monoclonal antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2003-09 |
| Est. Completion | 2007-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00078546
The ClinicalTrials.gov registry entry for NCT00078546 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EBV specific CTL Infusion is the first listed.
NCT00078546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00078546 about?
NCT00078546 is a clinical study titled "EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)". To determine the safety of the combination of CD45 monoclonal antibody (Mab) followed by intravenous injection of EBV specific CTL in patients with nasopharyngeal cancer. To compare the expansion, persistence and anti-tumor effects of the EBV specific CTL given after CD45 Mab administration with th...
What is the current status of trial NCT00078546?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2003-09. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00078546?
The interventions under investigation include: EBV specific CTL Infusion (BIOLOGICAL), Anti CD45 monoclonal antibody (BIOLOGICAL).
Who is sponsoring clinical trial NCT00078546?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.